At Pharmabiotics 2021 Conference & Partnering, Adrien Nivoliez, Biose Industrie CEO, held an Interactive Roundtable Discussion called Microbiome Therapeutics – the investment cycle from discovery to commercialization. Nivoliez spoke with […]
Using live microorganisms to enhance response to cancer immunotherapies is finally within reach. Cancer is the world’s leading cause of death, affecting people of all ages and socio-economic groups. […]
Hundreds of companies around the world are currently working on how to leverage human microbiome research for new clinical solutions – with at least €900M invested in microbiome-focused companies in 2020. The […]
Boston is one of the top global hubs for biotechnology companies developing live biotherapeutic products (LBPs), and many of these companies seek out the expertise of the world leading CDMO, […]
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live […]
A company that supports the process development and manufacturing of live biotherapeutic products (LBPs) needs to know bacteria inside out: not just the potential therapeutic effects of the strains, but […]
Live biotherapeutic products (LBPs), or live microorganisms employed as drugs, are relatively new on the pharmaceutical scene. Yet Biose Industrie CEO Adrien Nivoliez has his eye on the future. According […]
Aurillac, July 16, 2020 – Biose Industrie announced today the closing of a €30 million funding round led by Cathay Capital, alongside the company’s management team, banking partners and the […]
Contract Development & Manufacturing Organizations (CDMOs) are critical partners for moving ahead with new drug products. But with a growing number of start-up companies working to develop microbiome-based products, are CDMOs ready to […]